SG11201605903SA - Methods of using anti-steap1 antibodies and immunoconjugates - Google Patents

Methods of using anti-steap1 antibodies and immunoconjugates

Info

Publication number: SG11201605903SA
Authority: SG; Singapore
Prior art keywords: immunoconjugates; methods; steap1; antibodies; steap1 antibodies
Prior art date: 2014-01-24

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-01-23Application filed by Genentech IncfiledCriticalGenentech Inc

2016-08-30Publication of SG11201605903SApublicationCriticalpatent/SG11201605903SA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Botany (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SG11201605903SA2014-01-242015-01-23Methods of using anti-steap1 antibodies and immunoconjugatesSG11201605903SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201461931478P	2014-01-24	2014-01-24
PCT/US2015/012766WO2015112909A1 (en)	2014-01-24	2015-01-23	Methods of using anti-steap1 antibodies and immunoconjugates

Publications (1)

Publication Number	Publication Date
SG11201605903SAtrue SG11201605903SA (en)	2016-08-30

Family

ID=52463183

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201605903SASG11201605903SA (en)	2014-01-24	2015-01-23	Methods of using anti-steap1 antibodies and immunoconjugates

Country Status (14)

Country	Link
US (1)	US20170043034A1 (en)
EP (1)	EP3096797A1 (en)
JP (1)	JP2017505305A (en)
KR (1)	KR20160111469A (en)
CN (1)	CN106413756A (en)
AR (1)	AR099181A1 (en)
AU (1)	AU2015209154A1 (en)
BR (1)	BR112016015693A2 (en)
CA (1)	CA2935393A1 (en)
IL (1)	IL246489A0 (en)
MX (1)	MX2016009515A (en)
RU (1)	RU2016130349A (en)
SG (1)	SG11201605903SA (en)
WO (1)	WO2015112909A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2018524295A (en)*	2015-06-15	2018-08-30	ジェネンテック，インコーポレイテッド	Antibodies and immune complexes
PE20200010A1 (en)	2017-04-03	2020-01-06	Hoffmann La Roche	ANTIBODIES THAT JOIN STEAP-1
US11530274B2 (en)	2018-07-02	2022-12-20	Amgen Inc.	Anti-STEAP1 antigen-binding protein
CA3106653A1 (en)*	2018-07-18	2020-01-23	Amgen Inc.	Chimeric receptors to steap1 and methods of use thereof
KR20220057575A (en)*	2019-09-05	2022-05-09	메모리얼 슬로안 케터링 캔서 센터	Anti-STEAP1 antibodies and uses thereof
GB202208119D0 (en)*	2022-06-01	2022-07-13	Univ Oslo Hf	Anti-steap1 car

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US633410A (en)	1898-09-22	1899-09-19	George A Ames	Ice-cutter.
US3896111A (en)	1973-02-20	1975-07-22	Research Corp	Ansa macrolides
US4151042A (en)	1977-03-31	1979-04-24	Takeda Chemical Industries, Ltd.	Method for producing maytansinol and its derivatives
US4137230A (en)	1977-11-14	1979-01-30	Takeda Chemical Industries, Ltd.	Method for the production of maytansinoids
US4265814A (en)	1978-03-24	1981-05-05	Takeda Chemical Industries	Matansinol 3-n-hexadecanoate
US4307016A (en)	1978-03-24	1981-12-22	Takeda Chemical Industries, Ltd.	Demethyl maytansinoids
JPS5562090A (en)	1978-10-27	1980-05-10	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
US4256746A (en)	1978-11-14	1981-03-17	Takeda Chemical Industries	Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en)	1978-11-14	1980-05-20	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS55164687A (en)	1979-06-11	1980-12-22	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS55102583A (en)	1979-01-31	1980-08-05	Takeda Chem Ind Ltd	20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en)	1979-06-05	1980-12-18	Takeda Chem Ind Ltd	Antibiotic c-15003pnd and its preparation
JPS55164685A (en)	1979-06-08	1980-12-22	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS55164686A (en)	1979-06-11	1980-12-22	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
US4309428A (en)	1979-07-30	1982-01-05	Takeda Chemical Industries, Ltd.	Maytansinoids
JPS5645483A (en)	1979-09-19	1981-04-25	Takeda Chem Ind Ltd	C-15003phm and its preparation
EP0028683A1 (en)	1979-09-21	1981-05-20	Takeda Chemical Industries, Ltd.	Antibiotic C-15003 PHO and production thereof
JPS5645485A (en)	1979-09-21	1981-04-25	Takeda Chem Ind Ltd	Production of c-15003pnd
WO1981001145A1 (en)	1979-10-18	1981-04-30	Univ Illinois	Hydrolytic enzyme-activatible pro-drugs
WO1982001188A1 (en)	1980-10-08	1982-04-15	Takeda Chemical Industries Ltd	4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en)	1980-11-03	1984-05-22	Standard Oil Company	Impact improvement of high nitrile resins
US4313946A (en)	1981-01-27	1982-02-02	The United States Of America As Represented By The Secretary Of Agriculture	Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en)	1981-01-27	1982-02-16	The United States Of America As Represented By The Secretary Of Agriculture	Method of controlling the European corn borer with trewiasine
JPS57192389A (en)	1981-05-20	1982-11-26	Takeda Chem Ind Ltd	Novel maytansinoid
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
EP0368684B2 (en)	1988-11-11	2004-09-29	Medical Research Council	Cloning immunoglobulin variable domain sequences.
DE3920358A1 (en)	1989-06-22	1991-01-17	Behringwerke Ag	BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
CA2026147C (en)	1989-10-25	2006-02-07	Ravi J. Chari	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en)	1990-12-03	2003-02-04	Lisa J. Garrard	Enrichment method for variant proteins with altered binding properties
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
WO1992022653A1 (en)	1991-06-14	1992-12-23	Genentech, Inc.	Method for making humanized antibodies
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
US7018809B1 (en)	1991-09-19	2006-03-28	Genentech, Inc.	Expression of functional antibody fragments
US5362852A (en)	1991-09-27	1994-11-08	Pfizer Inc.	Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5587458A (en)	1991-10-07	1996-12-24	Aronex Pharmaceuticals, Inc.	Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en)	1992-02-06	1993-08-19	L.L. Houston	Biosynthetic binding protein for cancer marker
ZA932522B (en)	1992-04-10	1993-12-20	Res Dev Foundation	Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
ATE196606T1 (en)	1992-11-13	2000-10-15	Idec Pharma Corp	THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES DIRECTED AGAINST A DIFFERENTIATION ANTIGEN WHICH EXPRESSION IS RESTRICTED TO HUMAN B LYMPHOCYTES, FOR THE TREATMENT OF B-CELL LYMPHOMA
US5635483A (en)	1992-12-03	1997-06-03	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en)	1993-01-26	1998-07-14	Arizona Board Of Regents	Elucidation and synthesis of selected pentapeptides
US6214345B1 (en)	1993-05-14	2001-04-10	Bristol-Myers Squibb Co.	Lysosomal enzyme-cleavable antitumor drug conjugates
CA2163345A1 (en)	1993-06-16	1994-12-22	Susan Adrienne Morgan	Antibodies
KR100332254B1 (en)	1993-10-01	2002-09-27	데이꼬꾸 조끼 세이야꾸 가부시키가이샤	Novel Peptide Derivatives
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en)	1994-11-03	1998-08-04	Genentech, Inc.	Process for bacterial production of polypeptides
US5663149A (en)	1994-12-13	1997-09-02	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
PT994903E (en)	1997-06-24	2005-10-31	Genentech Inc	METHODS AND COMPOSITIONS FOR GALACTOSILED GLICOPROTEINS
US6040498A (en)	1998-08-11	2000-03-21	North Caroline State University	Genetically engineered duckweed
US6602677B1 (en)	1997-09-19	2003-08-05	Promega Corporation	Thermostable luciferases and methods of production
WO1999022764A1 (en)	1997-10-31	1999-05-14	Genentech, Inc.	Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en)	1997-11-24	2003-08-26	The Institute For Human Genetics And Biochemistry	Monoclonal human natural antibodies
ES2375931T3 (en)	1997-12-05	2012-03-07	The Scripps Research Institute	HUMANIZATION OF ANTIBODY MURINO.
WO1999051642A1 (en)	1998-04-02	1999-10-14	Genentech, Inc.	Antibody variants and fragments thereof
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
AU3657899A (en)	1998-04-20	1999-11-08	James E. Bailey	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
HUP0104865A3 (en)	1999-01-15	2004-07-28	Genentech Inc	Polypeptide variants with altered effector function
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
EP3031917A1 (en)	1999-04-09	2016-06-15	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
ATE303445T1 (en)	1999-10-04	2005-09-15	Medicago Inc	METHOD FOR REGULATION OF TRANSCRIPTION OF FOREIGN GENES IN THE PRESENCE OF NITROGEN
US7125978B1 (en)	1999-10-04	2006-10-24	Medicago Inc.	Promoter for regulating expression of foreign genes
JP4668498B2 (en)	1999-10-19	2011-04-13	協和発酵キリン株式会社	Method for producing polypeptide
IL149809A0 (en)	1999-12-15	2002-11-10	Genentech Inc	Shotgun scanning, a combinatorial method for mapping functional protein epitopes
HUP0300369A2 (en)	2000-04-11	2003-06-28	Genentech, Inc.	Multivalent antibodies and uses therefor
US6333410B1 (en)	2000-08-18	2001-12-25	Immunogen, Inc.	Process for the preparation and purification of thiol-containing maytansinoids
WO2002031140A1 (en)	2000-10-06	2002-04-18	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
CA2430013C (en)	2000-11-30	2011-11-22	Medarex, Inc.	Transgenic transchromosomal rodents for making human antibodies
US6884869B2 (en)	2001-04-30	2005-04-26	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
US6441163B1 (en)	2001-05-31	2002-08-27	Immunogen, Inc.	Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
NZ581474A (en)	2001-08-03	2011-04-29	Glycart Biotechnology Ag	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7091186B2 (en)	2001-09-24	2006-08-15	Seattle Genetics, Inc.	p-Amidobenzylethers in drug delivery agents
WO2003026577A2 (en)	2001-09-24	2003-04-03	Seattle Genetics, Inc.	P-amidobenzylethers in drug delivery agents
ATE430580T1 (en)	2001-10-25	2009-05-15	Genentech Inc	GLYCOPROTEIN COMPOSITIONS
WO2003043583A2 (en)	2001-11-20	2003-05-30	Seattle Genetics, Inc.	Treatment of immunological disorders using anti-cd30 antibodies
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
WO2003085118A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Process for producing antibody composition
US20040259150A1 (en)	2002-04-09	2004-12-23	Kyowa Hakko Kogyo Co., Ltd.	Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
EP1502603A4 (en)	2002-04-09	2006-12-13	Kyowa Hakko Kogyo Kk	DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM Fc gamma RIIIa POLYMORPHISM
CA2481920A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Antibody composition-containing medicament
ES2362419T3 (en)	2002-04-09	2011-07-05	Kyowa Hakko Kirin Co., Ltd.	CELLS WITH DEPRESSION OR DELETION OF THE ACTIVITY OF THE PROTEIN THAT PARTICIPATES IN THE TRANSPORT OF GDP-FUCOSA.
MXPA04009924A (en)	2002-04-09	2005-07-01	Kyowa Hakko Kogyo Kk	Cells with modified genome.
CA2488441C (en)	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
DK1545613T3 (en)	2002-07-31	2011-11-14	Seattle Genetics Inc	Auristatin conjugates and their use in the treatment of cancer, an autoimmune disease or an infectious disease
WO2004032828A2 (en)	2002-07-31	2004-04-22	Seattle Genetics, Inc.	Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
AU2003259163B2 (en)	2002-08-16	2008-07-03	Immunogen, Inc.	Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PL212899B1 (en)	2002-12-16	2012-12-31	Genentech Inc	Immunoglobulin variants and uses thereof
CA2510003A1 (en)	2003-01-16	2004-08-05	Genentech, Inc.	Synthetic antibody phage libraries
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en)	2003-03-05	2011-01-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7755007B2 (en)	2003-04-17	2010-07-13	K&H Manufacturing, Inc	Heated pet mat
US7276497B2 (en)	2003-05-20	2007-10-02	Immunogen Inc.	Cytotoxic agents comprising new maytansinoids
WO2005035586A1 (en)	2003-10-08	2005-04-21	Kyowa Hakko Kogyo Co., Ltd.	Fused protein composition
AU2004280065A1 (en)	2003-10-09	2005-04-21	Kyowa Hakko Kirin Co., Ltd.	Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
MX337587B (en)	2003-11-05	2016-03-11	Glycart Biotechnology Ag	Antigen binding molecules with increased fc receptor binding affinity and effector function.
SG10201701737XA (en)	2003-11-06	2017-04-27	Seattle Genetics Inc	Monomethylvaline compounds capable of conjugation to ligands
WO2005053742A1 (en)	2003-12-04	2005-06-16	Kyowa Hakko Kogyo Co., Ltd.	Medicine containing antibody composition
EP1718667B1 (en)	2004-02-23	2013-01-09	Genentech, Inc.	Heterocyclic self-immolative linkers and conjugates
US7527791B2 (en)	2004-03-31	2009-05-05	Genentech, Inc.	Humanized anti-TGF-beta antibodies
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
EP2357201B1 (en)	2004-04-13	2017-08-30	F. Hoffmann-La Roche AG	Anti-P-selectin antibodies
EP1753463A2 (en)	2004-06-01	2007-02-21	Genentech, Inc.	Antibody drug conjugates and methods
TWI309240B (en)	2004-09-17	2009-05-01	Hoffmann La Roche	Anti-ox40l antibodies
US20100111856A1 (en)	2004-09-23	2010-05-06	Herman Gill	Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2669510T3 (en)	2004-09-23	2018-05-28	Genentech, Inc.	Antibodies and conjugates engineered with cysteine
JO3000B1 (en)	2004-10-20	2016-09-05	Genentech Inc	Antibody Formulations.
EP1917020B1 (en)	2005-07-07	2016-05-25	Seattle Genetics, Inc.	Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
US8871720B2 (en)	2005-07-07	2014-10-28	Seattle Genetics, Inc.	Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
EP1957531B1 (en)	2005-11-07	2016-04-13	Genentech, Inc.	Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en)	2005-12-02	2007-06-07	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
AR060871A1 (en)	2006-05-09	2008-07-16	Genentech Inc	UNION OF POLYPEPTIDES WITH OPTIMIZED SUPERCONTIGES
DK2059533T3 (en)	2006-08-30	2013-02-25	Genentech Inc	MULTI-SPECIFIC ANTIBODIES
UA94628C2 (en)*	2006-10-27	2011-05-25	Дженентек, Инк.	Humanized monoclonal antibody that binds to steap-1 and use thereof
PL2061814T3 (en)	2006-10-27	2012-10-31	Genentech Inc	Antibodies and immunoconjugates and uses therefor
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
JP5394246B2 (en)*	2007-03-30	2014-01-22	ジェネンテック，インコーポレイテッド	Antibodies and immunoconjugates and methods for their use
CN100592373C (en)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	Liquid crystal panel drive device and its drive method
DK2235064T3 (en)	2008-01-07	2016-01-11	Amgen Inc	A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
KR20120034591A (en)*	2009-03-06	2012-04-12	어젠시스 인코포레이티드	Antibody drug conjugates (adc) that bind to 24p4c12 proteins

2015
- 2015-01-23JPJP2016547908Apatent/JP2017505305A/enactivePending
- 2015-01-23RURU2016130349Apatent/RU2016130349A/ennot_activeApplication Discontinuation
- 2015-01-23WOPCT/US2015/012766patent/WO2015112909A1/enactiveApplication Filing
- 2015-01-23USUS15/308,079patent/US20170043034A1/ennot_activeAbandoned
- 2015-01-23AUAU2015209154Apatent/AU2015209154A1/ennot_activeAbandoned
- 2015-01-23CNCN201580005483.7Apatent/CN106413756A/enactivePending
- 2015-01-23CACA2935393Apatent/CA2935393A1/ennot_activeAbandoned
- 2015-01-23KRKR1020167022661Apatent/KR20160111469A/ennot_activeWithdrawn
- 2015-01-23BRBR112016015693Apatent/BR112016015693A2/ennot_activeApplication Discontinuation
- 2015-01-23SGSG11201605903SApatent/SG11201605903SA/enunknown
- 2015-01-23EPEP15703385.3Apatent/EP3096797A1/ennot_activeWithdrawn
- 2015-01-23MXMX2016009515Apatent/MX2016009515A/enunknown
- 2015-01-26ARARP150100206Apatent/AR099181A1/enunknown
2016
- 2016-06-27ILIL246489Apatent/IL246489A0/enunknown

Also Published As

Publication number	Publication date
RU2016130349A (en)	2018-03-01
BR112016015693A2 (en)	2017-10-24
IL246489A0 (en)	2016-08-31
WO2015112909A1 (en)	2015-07-30
US20170043034A1 (en)	2017-02-16
EP3096797A1 (en)	2016-11-30
AU2015209154A1 (en)	2017-02-16
KR20160111469A (en)	2016-09-26
JP2017505305A (en)	2017-02-16
AR099181A1 (en)	2016-07-06
CN106413756A (en)	2017-02-15
CA2935393A1 (en)	2015-07-30
MX2016009515A (en)	2016-10-26
RU2016130349A3 (en)	2018-09-24

Publication	Publication Date	Title
IL279606A (en)	2021-03-01	Anti-trem2 antibodies and methods of use thereof
HK1243102A1 (en)	2018-07-06	Anti-cd79b antibodies and methods of use
HRP20181359T1 (en)	2018-10-19	Anti-jagged1 antibodies and methods of use
IL251868B (en)	2021-09-30	Anti-tim3 antibodies and methods of use
IL250461A0 (en)	2017-03-30	Anti-cll-1 antibodies and immunoconjugates
IL247898A0 (en)	2016-11-30	Anti-ox40 antibodies and methods of use
IL251165A0 (en)	2017-04-30	Anti-il-1beta antibodies and methods of use
IL247754A0 (en)	2016-11-30	Anti-mcam antibodies and associated methods of use
IL251286A0 (en)	2017-05-29	Anti-pdgf-b antibodies and methods of use
IL246489A0 (en)	2016-08-31	Methods of using anti-steap1 antibodies and immunoconjugates

Movatterモバイル変換

SG11201605903SA - Methods of using anti-steap1 antibodies and immunoconjugates - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=52463183

Family Applications (1)

Country Status (14)

Families Citing this family (6)

Family Cites Families (140)

Also Published As

Similar Documents